Back to discover
Disease

Systemic Inflammatory Response Syndrome

Late-stage therapeutic developmentEmerging researchCooling momentum
14
Publications
13
Clinical trials
6
Related conditions
2
Related proteins
2024
Latest publication
Current focus
Immunoglobulins biologyTherapeutic developmentInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Multisystem Inflammatory Syndrome in Children in New York State.

Research2020-06-29The New England journal of medicine

Cytokines in Inflammatory Disease.

Research2019-11-28International journal of molecular sciences

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Canakinumabapproved

Approval — Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinfla… (2009)

Anakinraapproved

Approval — Rheumatoid Arthritis (RA) Kineret is indicated in adults for the treatment of the signs a… (2002)

Clinical trials

13 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
13
All trials
5
Active
7
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2009emaApprovalCanakinumab· Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including: Muckle-Wells syndrome (MWS), Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD). Familial Mediterranean fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate. Ilaris is also indicated for the treatment of: Still’s disease Ilaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate. Gouty arthritis Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. source ↗
2002emaApprovalAnakinra· Rheumatoid Arthritis (RA) Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone. COVID-19 Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ? 6 ng/ml. Periodic fever syndromes Kineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above: Cryopyrin-Associated Periodic Syndromes (CAPS) Kineret is indicated for the treatment of CAPS, including: Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) Muckle-Wells Syndrome (MWS) Familial Cold Autoinflammatory Syndrome (FCAS) Familial Mediterranean Fever (FMF) Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate. Still’s Disease Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

14 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20162024
Recent publications
Major themes8
  • Systemic Inflammatory Response Syndrome2
  • Acute Lung Injury1
  • Coronary Aneurysm1
  • COVID-191
  • Heart1
  • Mucocutaneous Lymph Node Syndrome1
  • Nervous System Diseases1
  • Organ Dysfunction Scores1
Leading journals6
  • Arthritis & rheumatology (Hoboken, N.J.)3
  • JAMA2
  • Blood1
  • BMJ (Clinical research ed.)1
  • Cell1
  • European journal of pediatrics1
Leading researchers8
  • Friedman KG4
  • Henderson LA3
  • Bassiri H2
  • Behrens EM2
  • Canna SW2
  • Dionne A2
  • Ferris A2
  • Gorelik M2
Affiliations (unnormalised)6
  • University of Pittsburgh School of Medicine3
  • American College of Rheumatology2
  • Boston Children's Hospital2
  • Boston Children's Hospital and Harvard Medical School2
  • Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine.2
  • Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine2

Disease biology

2 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

6 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Systemic inflammatory response syndrome is a systemic inflammatory response to a range of clinical insults. It is characterized by at least two findings such as fever or hypothermia, tachycardia, tachypnea, and leukocytosis. It is often associated with infection, but it can also occur with noninfectious insults such as trauma, burns, or pancreatitis.

Causes

The grounding supports a broad etiologic category rather than a single cause. SIRS can be triggered by infection, and it can also follow noninfectious clinical insults including trauma, burns, and pancreatitis. The literature also links systemic inflammatory states to cytokine-mediated inflammatory disease and critical illness.

Pathophysiology

The condition reflects a systemic inflammatory state with involvement of inflammatory cytokines. The supplied reviews describe cytokines such as IL-6, IL-1, IL-33, TNF-α, IL-10, and IL-8 as mediators implicated in inflammatory disease, shock, trauma, immune dysregulation, and critical illness. In this context, SIRS is associated with cytokine-driven inflammation and, when severe, can be accompanied by widespread organ dysfunction.

Risk factors

The grounding supports exposure to clinical insults that can precipitate SIRS, including infection, trauma, burns, and pancreatitis. It also supports severe inflammatory states and critical illness as associated contexts. No additional patient-level risk factors are supported by the supplied material.

Current standard of care

The supplied material supports supportive management and treatment directed at the underlying trigger, but it does not provide a detailed standard regimen for SIRS itself. In related inflammatory syndromes, management may include immunomodulatory therapy and supportive care, and cytokines are discussed as potential biomarkers and therapeutic parameters. No specific drug class is established in the grounding as standard therapy for SIRS.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever >38 degrees C or HYPOTHERMIA <36 degrees C; (2) TACHYCARDIA >90 beat/minute; (3) tachypnea >24 breaths/minute; (4) LEUKOCYTOSIS >12,000 cells/cubic mm or 10% immature forms. While usually related to infection, SIRS can also be associated with noninfectious insults such as TRAUMA; BURNS; or PANCREATITIS. If infection is involved, a patient with SIRS is said to have SEPSIS.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.